MRNA Moderna Inc
Company Analysis
Latest News
Moderna Shares Plunge After Leak Shows 42% Cancer Risk Cut
Moderna shares fell more than 20% on Thursday after detailed results for its personalized melanoma vaccine, intismeran, developed with Merck, were apparently...
Moderna Drops 12% After a 700% Rally — Can a Single Data Readout Justify a $98 Billion Valuation?
Shares of Moderna plunged 11.9% to $216.65 on Thursday as investors locked in profits from a breathtaking cancer-vaccine rally, with the critical question now...
🔴 Moderna is trading 12% down today as investors reassess valuation before full trial data
Moderna is trading at $216.65 (-11.86%) as investors reassess its valuation after a sharp rally tied to positive Phase 3 melanoma-vaccine news. - Full data...
🔴 Moderna is trading 6% down today ahead of October 24 melanoma-vaccine data
Moderna is trading at $231.05, down 5.95%, as investors position ahead of full Phase 3 melanoma-vaccine data for intismeran with Merck, scheduled for October...
🔴 Moderna is trading 4.3% down amid a broad risk-off session
Moderna is trading at $237.92, with a -4.31% change, amid a broad risk-off session. - The Nasdaq Composite is down 1.57% and the S&P 500 is down 0.95%,...
🟢 Moderna is trading 4.03% up today amid melanoma-vaccine optimism
Moderna is trading 4.03% higher at $251.84 on October 21 as investors focus on positive Phase 3 results for its personalized melanoma vaccine with Merck. - The...
Moderna and Merck Prepare FDA Filing for Personalized Melanoma Vaccine
Moderna and Merck are preparing to seek FDA approval for intismeran autogene, a personalized mRNA vaccine for patients with high-risk melanoma that has been...
🟢 Moderna is trading 4.6% up today ahead of Phase 3 melanoma-vaccine data
Moderna is trading at $237.34, up 4.61%, as investors position ahead of the full Phase 3 melanoma-vaccine data presentation scheduled for October 24. - A...
🟢 Moderna is trading 7.2% up today with no clear company-specific catalyst
Moderna is trading at $233.72, up 7.21%, as of 9:41 a.m. EST on October 19, 2026; the cause of the rise remains uncertain. - Available reporting identifies no...
Moderna President Sells $17M in Stock, Ahead of Cancer Vaccine Data
Moderna President Stephen Hoge sold approximately $17.01 million in company stock. The transactions occurred on October 14 and 15, 2026. He executed the sales...
🔴 Moderna is trading 10.3% down today amid biotech-sector selling
Moderna is trading at $212.16, down 10.29%, amid an active biotech-sector selloff. - XBI was down 2.06% during the regular session. - Citi’s recent Sell...
🔴 Moderna is trading 5.8% down today, extending losses after Citi’s recent downgrade citing valuation concerns
- Moderna is trading 5.8% down at $222.80, with today's decline influenced by Citi's September 30, 2026, downgrade to Sell and its $80 price target, reflecting...
🟢 Moderna is trading 5% up
Moderna is trading 5.07% up at $237.77 on October 15, with no verified report tying the move to company-specific news and biotech strength offering a possible...
🟢 Moderna is trading 4.2% up without a clear catalyst
Moderna is trading up 4.2% at $225.34 on October 14; coverage describes an intraday rebound but identifies no clear catalyst. - The recent rally has been...
🔴 Moderna is trading 4.04% down today in a post-rally pullback
Moderna is trading 4.04% down at $215.91 on October 12, in a pullback following Friday’s sharp rally. - No fresh company-specific announcement explaining the...
🟢 Moderna is trading 10% up today after Nasdaq-100 inclusion, with possible index-fund buying
Moderna is trading at $217.37, up 10.34%, with its Nasdaq-100 inclusion the clearest company-specific catalyst. - The inclusion took effect before the market...
Moderna's 8% Pop on Nasdaq-100 Inclusion: Can Passive Fund Buying Sustain a Stock That Has Struggled for Years?
Shares of Moderna surged 8.3% to $213.38 on October 9 as the biotech's addition to the Nasdaq-100 index took effect before the opening bell, forcing billions...
🟢 Moderna is trading 8% up today amid potential Nasdaq-100 fund buying
Moderna is trading 8.31% higher at $213.38, with Nasdaq-100 inclusion-related buying the clearest catalyst. - Nasdaq confirmed the addition, effective before...
Moderna Launches First mRNA Flu Vaccine, mFlusiva, for 2026–27 Season
Moderna’s first mRNA-based seasonal flu vaccine, mFlusiva, is now available in the U.S. for the 2026–2027 flu season. [4, 11] The FDA approved it in August...
🟢 Moderna is trading 4.08% up amid expanded Tempus cancer-therapy collaboration
Moderna is trading 4.08% up at $195.10 on October 7, 2026, amid Tempus’s expanded collaboration with Moderna and Merck; available reporting does not establish...